Transcriptomic analysis reveals reduced transcriptional activity in the malaria parasite Plasmodium cynomolgi during progression into dormancy

Abstract

Relapses of Plasmodium dormant liver hypnozoites compromise malaria eradication efforts. New radical cure drugs are urgently needed, yet the vast gap in knowledge of hypnozoite biology impedes drug discovery. We previously unraveled the transcriptome of 6 to 7 day-old P. cynomolgi liver stages, highlighting pathways associated with hypnozoite dormancy (Voorberg-van der Wel, 2017). We now extend these findings by transcriptome profiling of 9 to 10 day-old liver stage parasites, thus revealing for the first time the maturation of the dormant stage over time. Although progression of dormancy leads to a 10-fold decrease in transcription and expression of only 840 genes, including genes associated with housekeeping functions, we show that pathways involved in quiescence, energy metabolism and maintenance of genome integrity remain the prevalent pathways active in mature hypnozoites.

Data availability

The raw RNA-sequencing reads are available in the NCBI Short Read Archive (https://www.ncbi.nlm.nih.gov/sra) under accession number SRP096160.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Nicole L Bertschi

    Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Nicole L Bertschi, employed by and/or shareholders of Novartis Pharma AG.
  2. Annemarie Voorberg-van der Wel

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9403-0515
  3. Anne-Marie Zeeman

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
  4. Sven Schuierer

    Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Sven Schuierer, employed by and/or shareholders of Novartis Pharma AG.
  5. Florian Nigsch

    Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Florian Nigsch, employed by and/or shareholders of Novartis Pharma AG.
  6. Walter Carbone

    Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Walter Carbone, employed by and/or shareholders of Novartis Pharma AG.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6150-8295
  7. Judith Knehr

    Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Judith Knehr, employed by and/or shareholders of Novartis Pharma AG.
  8. Devendra Kumar Gupta

    Novartis Institute for Tropical Diseases, Emeryville, United States
    Competing interests
    Devendra Kumar Gupta, employed by and/or shareholders of Novartis Pharma AG.
  9. Sam O Hofman

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
  10. Nicole van der Werff

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
  11. Ivonne Nieuwenhuis

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
  12. Els Klooster

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
  13. Bart W Faber

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
  14. Erika L Flannery

    Novartis Institute for Tropical Diseases, Emeryville, United States
    Competing interests
    Erika L Flannery, employed by and/or shareholders of Novartis Pharma AG.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0665-7954
  15. Sebastian Mikolajczak

    Novartis Institute for Tropical Diseases, Emeryville, United States
    Competing interests
    Sebastian Mikolajczak, employed by and/or shareholders of Novartis Pharma AG.
  16. Binesh Shrestha

    Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Binesh Shrestha, employed by and/or shareholders of Novartis Pharma AG.
  17. Martin Beibel

    Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Martin Beibel, employed by and/or shareholders of Novartis Pharma AG.
  18. Tewis Bouwmeester

    Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Tewis Bouwmeester, employed by and/or shareholders of Novartis Pharma AG.
  19. Niwat Kangwanrangsan

    Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok, Thailand
    Competing interests
    No competing interests declared.
  20. Jetsumon Sattabongkot

    Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3938-4588
  21. Thierry Tidiane Diagana

    Novartis Institute for Tropical Diseases, Emeryville, United States
    Competing interests
    Thierry Tidiane Diagana, employed by and/or shareholders of Novartis Pharma AG.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8520-5683
  22. Clemens H M Kocken

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    For correspondence
    kocken@bprc.nl
    Competing interests
    No competing interests declared.
  23. Guglielmo Roma

    Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland
    For correspondence
    guglielmo.roma@novartis.com
    Competing interests
    Guglielmo Roma, employed by and shareholders of Novartis Pharma AG.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8020-4219

Funding

Bill and Melinda Gates Foundation

  • Thierry Tidiane Diagana
  • Clemens H M Kocken
  • Guglielmo Roma

Wellcome

  • Thierry Tidiane Diagana
  • Clemens H M Kocken

Medicines for Malaria Venture

  • Thierry Tidiane Diagana
  • Clemens H M Kocken

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Nonhuman primates were used because no other models (in vitro or in vivo) were suitable for the aims of this project. The research protocol was approved by the local independent ethical committee conform Dutch law (BPRC Dier Experimenten Commissie, DEC, agreement number #708). Details are described by Voorberg-van der Wel [4].

Reviewing Editor

  1. Urszula Krzych, Walter Reed Army Institute of Research, United States

Publication history

  1. Received: August 28, 2018
  2. Accepted: December 23, 2018
  3. Accepted Manuscript published: December 27, 2018 (version 1)
  4. Version of Record published: January 23, 2019 (version 2)

Copyright

© 2018, Bertschi et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,143
    Page views
  • 430
    Downloads
  • 25
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Nicole L Bertschi
  2. Annemarie Voorberg-van der Wel
  3. Anne-Marie Zeeman
  4. Sven Schuierer
  5. Florian Nigsch
  6. Walter Carbone
  7. Judith Knehr
  8. Devendra Kumar Gupta
  9. Sam O Hofman
  10. Nicole van der Werff
  11. Ivonne Nieuwenhuis
  12. Els Klooster
  13. Bart W Faber
  14. Erika L Flannery
  15. Sebastian Mikolajczak
  16. Binesh Shrestha
  17. Martin Beibel
  18. Tewis Bouwmeester
  19. Niwat Kangwanrangsan
  20. Jetsumon Sattabongkot
  21. Thierry Tidiane Diagana
  22. Clemens H M Kocken
  23. Guglielmo Roma
(2018)
Transcriptomic analysis reveals reduced transcriptional activity in the malaria parasite Plasmodium cynomolgi during progression into dormancy
eLife 7:e41081.
https://doi.org/10.7554/eLife.41081

Further reading

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Taylor B Engdahl, Elad Binshtein ... James E Crowe Jr.
    Research Article

    Hantaviruses are high-priority emerging pathogens carried by rodents and transmitted to humans by aerosolized excreta or, in rare cases, person-to-person contact. While infections in humans are relatively rare, mortality rates range from 1 to 40% depending on the hantavirus species. There are currently no FDA-approved vaccines or therapeutics for hantaviruses, and the only treatment for infection is supportive care for respiratory or kidney failure. Additionally, the human humoral immune response to hantavirus infection is incompletely understood, especially the location of major antigenic sites on the viral glycoproteins and conserved neutralizing epitopes. Here, we report antigenic mapping and functional characterization for four neutralizing hantavirus antibodies. The broadly neutralizing antibody SNV-53 targets an interface between Gn/Gc, neutralizes through fusion inhibition and cross-protects against the Old World hantavirus species Hantaan virus when administered pre- or post-exposure. Another broad antibody, SNV-24, also neutralizes through fusion inhibition but targets domain I of Gc and demonstrates weak neutralizing activity to authentic hantaviruses. ANDV-specific, neutralizing antibodies (ANDV-5 and ANDV-34) neutralize through attachment blocking and protect against hantavirus cardiopulmonary syndrome (HCPS) in animals but target two different antigenic faces on the head domain of Gn. Determining the antigenic sites for neutralizing antibodies will contribute to further therapeutic development for hantavirus-related diseases and inform the design of new broadly protective hantavirus vaccines.

    1. Cancer Biology
    2. Microbiology and Infectious Disease
    Gabriel J Starrett, Kelly Yu ... Eric A Engels
    Research Article

    A small percentage of bladder cancers in the general population have been found to harbor DNA viruses. In contrast, up to 25% of tumors of solid organ transplant recipients, who are at an increased risk of developing bladder cancer and have overall poorer outcome, harbor BK polyomavirus (BKPyV). To better understand the biology of the tumors and the mechanisms of carcinogenesis from potential oncoviruses, we performed whole genome and transcriptome sequencing on bladder cancer specimens from 43 transplant patients. Nearly half of tumors from this patient population contained viral sequences. The most common were from BKPyV (N=9, 21%), JC polyomavirus (N=7, 16%), carcinogenic human papillomaviruses (N=3, 7%), and torque teno viruses (N=5, 12%). Immunohistochemistry revealed variable Large T antigen expression in BKPyV-positive tumors ranging from 100% positive staining of tumor tissue to less than 1%. In most cases of BKPyV-positive tumors, the viral genome appeared to be clonally integrated into the host chromosome consistent with microhomology-mediated end joining and coincided with focal amplifications of the tumor genome similar to other virus-mediated cancers. Significant changes in host gene expression consistent with the functions of BKPyV Large T antigen were also observed in these tumors. Lastly, we identified four mutation signatures in our cases with those attributable to APOBEC3 and SBS5 being the most abundant. Mutation signatures associated with the antiviral drug, ganciclovir, and aristolochic acid, a nephrotoxic compound found in some herbal medicines, were also observed. The results suggest multiple pathways to carcinogenesis in solid organ transplant recipients with a large fraction being virus-associated.